Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics, Inc. (FULC) is the issuer in an amended beneficial-ownership report by Bank of America Corporation, which reports beneficial ownership of 1,114,867 common shares, or 1.5% of the class. Bank of America reported shared voting power and shared dispositive power over all 1,114,867 shares, with zero sole voting or dispositive power. The ownership percentage uses 76,297,257 shares outstanding as of July 23, 2026, according to Fulcrum's Form 10-Q.
BlackRock Portfolio Management LLC reported beneficial ownership of 6,155,437 shares of Fulcrum Therapeutics, Inc. common stock, equal to 8.1% of the class. It reported sole voting power over 5,436,791 shares and sole dispositive power over 6,155,437 shares, with no shared voting or dispositive power.
Fulcrum Therapeutics, Inc. has agreed to combine with Slate Medicines, Inc. through a two-step merger, subject to required stockholder approvals and other closing conditions. Each Slate share is estimated to convert into approximately 24.8186 Fulcrum shares, based on capitalization as of August 16, 2026; the estimate excludes the proposed reverse stock split and is subject to adjustment based on Fulcrum’s estimated Net Cash at closing.
Slate investors agreed to purchase shares immediately before the merger for aggregate proceeds of approximately $245.0 million, subject to closing conditions. Based on current assumptions, former Slate holders excluding investors are expected to own 55.9%, investors 39.1%, and pre-merger Fulcrum holders 5.0% of the combined company on a fully diluted basis. Fulcrum expects an aggregate pre-closing cash dividend of approximately $270 million, tied to expected Net Cash above $20.3 million. The combined company is expected to be renamed Slate Medicines, Inc. and trade on Nasdaq as SLTE, subject to listing approval.
Fulcrum discontinued pociredir after FDA feedback and ceased active research and development following an approximately 85% workforce reduction; it had eight full-time employees as of September 30, 2026.
Fulcrum Therapeutics, Inc. (FULC) agreed on August 16, 2026, to merge with Slate Medicines, subject to stockholder approvals and other closing conditions. At the first effective time, each eligible Slate common share will convert at an estimated ratio of 24.8186 Fulcrum shares per Slate share, based on August 16 capitalization; the ratio may adjust for Fulcrum’s estimated Net Cash at closing and does not reflect the proposed reverse stock split.
Slate investors agreed to purchase Slate common stock for approximately $245.0 million immediately before the merger, subject to closing conditions; those shares will convert into Fulcrum shares. Fulcrum expects an aggregate pre-closing cash dividend of approximately $270 million, tied to expected closing Net Cash above $20.3 million. On a fully diluted basis, estimated ownership is 55.9% for pre-merger Slate holders excluding investors, 39.1% for investors, and 5.0% for pre-merger Fulcrum holders.
Fulcrum discontinued pociredir development in June 2026 following FDA concerns and ceased active research and development. It reduced its workforce by approximately 85% as of June 26, 2026, and had eight full-time employees as of September 30, 2026. The combined company is expected to be renamed Slate Medicines and trade under SLTE if its Nasdaq listing is approved.
Fulcrum Therapeutics, Inc. (FULC) is the issuer for a Rule 144 notice filed by former officer Greg Tourangeau covering planned sales of company common stock. The notice lists 14,062 shares of Fulcrum common stock with an approximate value of $54,419.94 as of September 2, 2026. The shares derive from various equity awards and programs, including restricted stock awards and units, stock option exercises, and purchases under the employee stock purchase program between 2018 and 2025.
Fulcrum Therapeutics, Inc. (FULC) filed a Form S-4 describing a stock-for-stock merger in which Fulcrum will acquire Slate Medicines through two merger subsidiaries, with Slate becoming the operating business of the combined company. Slate stockholders’ shares will be converted into Fulcrum common stock at an Exchange Ratio currently estimated at 24.8186 Fulcrum shares per Slate share, subject to adjustment based on Fulcrum’s Net Cash at closing and before any proposed reverse stock split.
Based on current assumptions, legacy Slate stockholders are expected to own 55.9%, new investors participating in a $245.0 million concurrent Slate financing 39.1%, and pre‑merger Fulcrum stockholders only 5.0% of the combined company on a fully diluted basis. Immediately prior to closing, Fulcrum expects to pay its stockholders a Pre‑Closing Cash Dividend estimated at about $270 million, leaving targeted Net Cash of roughly $20.3 million in the combined entity.
Fulcrum plans a reverse stock split, subject to stockholder approval, primarily to support continued Nasdaq listing, after which the combined company will be renamed Slate Medicines, Inc. and is expected to trade under the symbol SLTE. The transaction is intended to qualify as a tax‑free reorganization and will be accounted for as a reverse merger, with Slate treated as the accounting acquirer. Completion is subject to stockholder approvals, Nasdaq listing confirmation and other closing conditions, and both companies highlight extensive merger‑related and business risks.
Fulcrum Therapeutics and Slate Medicines have entered into a definitive agreement to merge in an all-stock transaction. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq under the ticker “SLTE”, focusing on Slate’s pipeline, including SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody being developed for prevention of migraine and other headache disorders.
In connection with the merger, Slate obtained a $245 million oversubscribed private placement from healthcare investors led by Frazier Life Sciences, which is expected to fund combined-company operations into 2029 as development of SLTE-1009 proceeds into a Phase 1 healthy volunteer study and a Phase 2 dose-range finding study in migraine patients. The private placement is expected to close concurrently with the merger, each subject to customary closing conditions, stockholder approvals, regulatory clearances and other risks described in Fulcrum’s disclosures.
Fulcrum Therapeutics and Slate Medicines plan to merge in an all-stock transaction, creating a combined company focused on migraine therapeutics. A $245 million private placement in Slate’s common stock and equivalents, led by multiple healthcare investors, is expected to help fund clinical development and provide cash runway into 2029.
On a fully diluted basis, pre-merger Fulcrum stockholders are expected to own 5% of the combined company, Slate stockholders 55.9%, and private placement investors 39.1%. Fulcrum expects to contribute $20.3 million of net cash for that 5% stake, and with approximately $270 million of additional cash at closing, intends to pay a special cash dividend to pre-merger Fulcrum stockholders. The combined company is expected to be renamed Slate Medicines, Inc. and trade on Nasdaq under the symbol SLTE, with Slate’s current CEO and board leading the organization.
Slate’s lead candidate, SLTE‑1009, is a monoclonal antibody targeting PACAP and VIP for migraine prevention, with a Phase 1 healthy volunteer study cleared in Australia and topline data anticipated mid‑2027, followed by a Phase 2 study in migraine patients in the second half of 2027. A second program, SLTE‑2100, a bispecific antibody targeting PACAP/VIP and CGRP, is expected to enter clinical trials in the second half of 2027. The companies expect the merger to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals and other customary conditions.
Fulcrum Therapeutics, Inc. plans a stock-for-stock merger with Slate Medicines, Inc. in a two-step transaction where Slate first merges into a Fulcrum subsidiary and then into a second subsidiary, leaving Fulcrum as the public parent renamed Slate Medicines, Inc. and effecting a Nasdaq reverse stock split.
Based on the agreed Exchange Ratio, Slate stockholders (excluding new investors) are expected to hold about 55.9% of the combined company on a fully diluted basis, Investors in a concurrent private placement about 39.1%, and pre‑merger Fulcrum stockholders about 5.0%, subject to net cash adjustments. The structure assumes a $31.3 million valuation for Fulcrum (adjusted to its closing net cash), a $350.0 million valuation for Slate and a $245.0 million concurrent investment into Slate whose shares will convert into Fulcrum stock at closing. Fulcrum expects to distribute an aggregate $270 million cash dividend to its pre‑merger stockholders, subject to adjustment, and all in‑the‑money options and RSUs at Fulcrum will vest or continue on adjusted terms, while out‑of‑the‑money options above $7.00 will be cancelled. Closing depends on stockholder approvals, HSR clearance, S‑4 effectiveness, Nasdaq listing and Fulcrum having non‑negative net cash.
Fulcrum Therapeutics, Inc. is combining with Slate Medicines, Inc. in an all‑stock merger structured as a two‑step merger, after which Slate will be a wholly owned subsidiary and the combined company will focus on Slate’s migraine portfolio. The merger values Slate at $350.0 million and Fulcrum at $31.3 million for exchange‑ratio purposes and is intended to qualify as a tax‑free reorganization. On a fully diluted, pro forma basis including the concurrent financing, pre‑merger Slate stockholders are expected to own 55.9%, the new investors 39.1%, and pre‑merger Fulcrum stockholders 5.0% of the combined company, subject to net‑cash‑based adjustments. Slate has secured an oversubscribed private placement of approximately $245 million, and the combined company’s cash is expected to fund operations into 2029. Immediately prior to closing, Fulcrum expects to pay pre‑merger Fulcrum stockholders a cash dividend estimated at $270.0 million and contribute about $20.3 million in net cash to the combined entity. The combined company will be renamed Slate Medicines, Inc., is expected to trade on Nasdaq under “SLTE,” and will be led by Slate’s management team, with Slate designating all five board members. Closing is targeted for the fourth quarter of 2026, subject to shareholder approvals, HSR clearance, Nasdaq listing, effectiveness of a Form S‑4 registration statement, a reverse stock split, minimum net‑cash and completion of the private placement.